In arrivo
Pharmacology & Therapeutics
Scegli il farmaco giusto, la dose giusta, e sappi perché.
Il corso completo
- moduli
- 83
- argomenti
- 1081
- min per lezione
- 15
Quello che saprai fare.
Calcola le dosi dai dati farmacocinetici
Tappa 1 · Drug Action & Pharmacokinetics
Individua le interazioni prima che arrivino ai pazienti
Tappa 2 · Safety, Evidence & Populations
Costruisci terapie per malattie cardiache e metaboliche
Tappa 4 · Organ-System Therapeutics
Scegli gli antibiotici pensando all'uso responsabile
Tappa 5 · Anti-Infectives & Oncology
Rivedi le terapie e sospendi i farmaci in sicurezza
Tappa 6 · Specialist Care & Medication Safety
Gestisci un caso complesso di politerapia
Tappa 7 · Practicum & Capstone
Sette tappe.Una salita costante.
Ogni grande classe di farmaci, organo per organo — poi il paziente che ne prende diversi insieme.
83moduli
in 7 tappe
1081argomenti
≈ 13 per modulo
≈270ore
in lezioni da 15 minuti
≈3anni
≈18mesi
≈9mesi
per finire l'intero corso
- 1
Drug Action & Pharmacokinetics
Cosa fa il farmaco, cosa fa il corpo
13 moduli · 170 argomenti · ≈ 43 h
- 2
Safety, Evidence & Populations
Quando i farmaci aiutano e quando fanno male
12 moduli · 160 argomenti · ≈ 40 h
- 3
Nervous System Pharmacology
Farmaci per dolore, umore, sonno e crisi epilettiche
14 moduli · 173 argomenti · ≈ 43 h
- 4
Organ-System Therapeutics
Cuore, polmoni, intestino, ormoni, immunità
19 moduli · 249 argomenti · ≈ 62 h
- 5
Anti-Infectives & Oncology
La lotta a infezioni e cancro
14 moduli · 184 argomenti · ≈ 46 h
- 6
Specialist Care & Medication Safety
Terapia intensiva, intossicazioni, prescrizioni più sicure
8 moduli · 107 argomenti · ≈ 27 h
- 7
Practicum & Capstone
Casi reali, molti farmaci insieme
3 moduli · 38 argomenti · ≈ 10 h
Mesi
061218240369120246
MesiTraguardo · ≈ 3 anni · ≈ 18 mesi · ≈ 9 mesi
Ore e mesi sono stime: una lezione da 15 minuti per argomento, ogni giorno.
Ogni modulo.Ogni argomento.
I titoli di moduli e argomenti restano in inglese, la lingua in cui lavora questo settore.
Tappa 1
Drug Action & Pharmacokinetics
Cosa fa il farmaco, cosa fa il corpo
13 moduli · 170 argomenti
1Foundations of Pharmacology and Therapeutics11 argomenti
- Pharmacology, Clinical Pharmacology, and Pharmacotherapy
- Medicines, Active Ingredients, and Therapeutic Products
- Generic Names, Brand Names, and Drug Classifications
- Molecular Mechanisms and Clinical Effects
- Prevention, Symptom Relief, and Disease Modification
- Therapeutic Indications and Treatment Objectives
- Efficacy, Effectiveness, and Individual Benefit
- Dose, Exposure, Response, and Outcome
- Therapeutic Benefits, Harms, and Treatment Burden
- Local and Systemic Drug Actions
- Individualized Treatment and Shared Decisions
2Molecular Targets and Drug Action14 argomenti
- Receptors as Pharmacological Targets
- G Protein-Coupled Receptors
- Ligand-Gated Ion Channels
- Voltage-Gated Ion Channels
- Enzyme-Linked Receptors
- Intracellular and Nuclear Receptors
- Enzymes as Drug Targets
- Transporters, Pumps, and Carrier Proteins
- Nucleic Acids and Structural Proteins as Targets
- Orthosteric and Allosteric Binding
- Reversible and Irreversible Target Binding
- Stereoselectivity in Drug Action
- Selectivity, Specificity, and Off-Target Effects
- Drugs with Physical or Chemical Mechanisms of Action
3Quantitative Pharmacodynamics14 argomenti
- Drug Binding and Receptor Occupancy
- Affinity, Dissociation Constants, and Binding Capacity
- Graded Dose-Response Relationships
- Concentration-Response Curves
- Potency and Maximal Effect
- Full Agonists, Partial Agonists, and Inverse Agonists
- Competitive and Noncompetitive Antagonism
- Functional and Chemical Antagonism
- Receptor Reserve and Signal Amplification
- Hill Slopes and Cooperative Responses
- Quantal Dose-Response Relationships
- Therapeutic Index and Therapeutic Window
- Additivity, Synergy, and Antagonism in Drug Combinations
- Interpreting Shifts in Dose-Response Curves
4Time-Dependent Effects and Variability in Response12 argomenti
- Onset, Peak Effect, and Duration of Action
- Delayed Effects and Indirect Responses
- Receptor Desensitization and Internalization
- Receptor Upregulation and Downregulation
- Tolerance and Tachyphylaxis
- Sensitization and Cumulative Effects
- Physical Dependence and Withdrawal
- Rebound Effects After Treatment Discontinuation
- Circadian Variation and Timing of Therapy
- Disease-Related Changes in Drug Response
- Placebo, Nocebo, and Contextual Effects
- Interindividual and Intraindividual Variability
5Physicochemical Foundations of Drug Disposition11 argomenti
- Molecular Size and Membrane Permeability
- Lipid Solubility and Aqueous Solubility
- Ionization, pH, and pKa
- Applying the Henderson-Hasselbalch Relationship
- Passive Diffusion and Facilitated Transport
- Active Uptake and Efflux
- Ion Trapping Across Biological Compartments
- Dissolution and Solubility-Limited Absorption
- Protein Binding and Free Drug Concentrations
- Chemical Stability in Biological Environments
- Prodrugs and Active Metabolites
6Routes of Administration and Dosage Forms16 argomenti
- Oral Tablets, Capsules, and Liquids
- Immediate-Release and Modified-Release Formulations
- Enteric Coatings and Site-Specific Release
- Sublingual and Buccal Administration
- Intravenous, Intramuscular, and Subcutaneous Administration
- Inhaled and Intranasal Medicines
- Topical and Transdermal Delivery
- Ophthalmic and Otic Formulations
- Rectal and Vaginal Administration
- Depot Injections and Long-Acting Formulations
- Intrathecal and Other Specialized Routes
- Choosing a Route for the Therapeutic Objective
- Formulation Switching and Product Substitution
- Administration Technique as a Determinant of Exposure
- Tablet Splitting, Crushing, and Feeding-Tube Compatibility
- Injectable Medicine Compatibility, Dilution, and Stability
7Drug Absorption and Bioavailability13 argomenti
- Rate and Extent of Absorption
- Gastrointestinal pH, Motility, and Transit Time
- Food Effects on Drug Absorption
- Intestinal Uptake and Efflux Transporters
- Intestinal and Hepatic First-Pass Metabolism
- Absolute and Relative Bioavailability
- Peak Concentration and Time to Peak Concentration
- Area Under the Concentration-Time Curve
- Presystemic Loss and Extraction
- Absorption After Nonoral Administration
- Bioequivalence and Its Clinical Interpretation
- Malabsorption and Altered Gastrointestinal Anatomy
- Formulation-Dependent Differences in Exposure
8Drug Distribution12 argomenti
- Apparent Volume of Distribution
- Tissue Perfusion and Distribution Rate
- Albumin and Alpha-1-Acid Glycoprotein Binding
- Unbound and Total Drug Concentrations
- Tissue Binding and Drug Reservoirs
- Blood-Brain Barrier Penetration
- Placental Transfer and Fetal Exposure
- Distribution into Breast Milk
- Distribution into Adipose Tissue and Body Water
- Edema, Ascites, and Fluid Shifts
- Redistribution and Termination of Drug Effects
- Intracellular Accumulation and Site-of-Action Exposure
9Drug Metabolism13 argomenti
- Phase I and Phase II Biotransformation
- Cytochrome P450 Enzyme Families
- Oxidation, Reduction, and Hydrolysis
- Glucuronidation and Other Conjugation Pathways
- Extrahepatic Drug Metabolism
- Metabolic Activation of Prodrugs
- Active and Toxic Metabolites
- Enzyme Inhibition and Its Time Course
- Enzyme Induction and Its Time Course
- Saturable Metabolism and Nonlinear Exposure
- Hepatic Blood Flow and Extraction Ratio
- Enterohepatic Recirculation
- Genetic and Environmental Influences on Metabolism
10Drug Excretion and Clearance12 argomenti
- Clearance as an Organ and Whole-Body Concept
- Glomerular Filtration of Drugs
- Active Tubular Secretion
- Tubular Reabsorption and Urinary pH
- Renal Transporter-Mediated Elimination
- Biliary and Intestinal Excretion
- Pulmonary Elimination
- Renal and Nonrenal Contributions to Clearance
- Clearance of Active Metabolites
- Drug Removal by Dialysis
- Changes in Clearance During Acute Illness
- Distinguishing Elimination Rate from Clearance
11Quantitative Pharmacokinetics14 argomenti
- Concentration-Time Curves and Sampling Design
- First-Order and Capacity-Limited Elimination
- Elimination Rate Constants and Half-Life
- Relationships Among Clearance, Volume, and Half-Life
- One-Compartment Models
- Two-Compartment Models and Distribution Phases
- Intravenous Bolus and Infusion Profiles
- Extravascular Absorption Models
- Multiple Dosing and Drug Accumulation
- Steady State and Fluctuation
- Noncompartmental Pharmacokinetic Analysis
- Nonlinear Pharmacokinetics
- Population Variability and Model Assumptions
- Limits of Pharmacokinetic Parameter Estimates
12Dosage Regimens and Pharmaceutical Calculations14 argomenti
- Units, Concentrations, and Dimensional Analysis
- Mass, Volume, Moles, and Equivalents
- Percentage Strengths and Concentration Expressions
- Loading Dose Calculations
- Maintenance Dose Calculations
- Dosing Intervals and Peak-Trough Fluctuation
- Infusion Rate Calculations
- Weight-Based and Body-Surface-Area-Based Dosing
- Actual, Ideal, and Adjusted Body Weight
- Dose Adjustments for Changes in Clearance
- Oral-to-Intravenous Conversion Principles
- Cumulative Exposure and Maximum Dose Checks
- Rounding, Precision, and Independent Calculation Checks
- Detecting Unit and Decimal Errors
13Exposure-Response Relationships and Therapeutic Drug Monitoring14 argomenti
- Linking Pharmacokinetics to Pharmacodynamics
- Plasma Concentrations and Effect-Site Concentrations
- Exposure-Response and Exposure-Toxicity Relationships
- Peak, Trough, and AUC-Based Monitoring
- Selecting Medicines for Therapeutic Drug Monitoring
- Sampling Time and Interpretation of Results
- Steady-State and Non-Steady-State Samples
- Interpreting Total and Unbound Drug Levels
- Active Metabolites in Concentration Monitoring
- Bayesian Dose Adjustment Concepts
- Biomarkers of Drug Effect and Toxicity
- Investigating Unexpected Drug Concentrations
- Clinical Response When Concentrations Are Within Range
- Integrating Laboratory Results with Treatment Decisions
Tappa 2
Safety, Evidence & Populations
Quando i farmaci aiutano e quando fanno male
12 moduli · 160 argomenti
14Drug Interactions15 argomenti
- Pharmacokinetic and Pharmacodynamic Interactions
- Changes in Absorption and Gastric pH
- Chelation and Binding in the Gastrointestinal Tract
- Metabolic Enzyme Inhibition and Induction
- Drug Transporter Interactions
- Protein-Binding Interactions and Their Clinical Relevance
- Additive Sedation and Respiratory Depression
- Additive Bleeding and Electrolyte Risks
- QT-Prolonging Drug Combinations
- Serotonergic and Anticholinergic Burden
- Drug-Food and Drug-Alcohol Interactions
- Interactions with Herbal and Nutritional Products
- Interaction Onset, Persistence, and Offset
- Evaluating Interaction Severity and Evidence
- Avoidance, Substitution, Separation, and Monitoring Strategies
15Adverse Drug Reactions and Hypersensitivity13 argomenti
- Adverse Events and Adverse Drug Reactions
- Dose-Related and Unpredictable Reactions
- Immediate and Delayed Drug Hypersensitivity
- Immune and Nonimmune Drug Reactions
- Anaphylaxis as a Medication-Related Emergency
- Severe Cutaneous Adverse Reactions
- Cross-Reactivity and Class Effects
- Drug Allergy, Intolerance, and Side Effects
- Timing, Dechallenge, and Rechallenge Evidence
- Causality Assessment and Competing Explanations
- Documenting Reaction Phenotypes and Severity
- Allergy Evaluation and Delabeling Principles
- Avoiding Re-Exposure After Serious Reactions
16Organ Toxicity and Medication-Related Syndromes14 argomenti
- Drug-Induced Liver Injury
- Drug-Induced Kidney Injury
- Drug-Induced Arrhythmias and QT Prolongation
- Medication-Related Heart Failure and Vascular Injury
- Pulmonary Toxicity
- Bone Marrow Suppression and Cytopenias
- Ototoxicity and Ocular Toxicity
- Peripheral Neuropathy and Central Neurotoxicity
- Drug-Induced Myopathy and Rhabdomyolysis
- Serotonin Syndrome and Neuroleptic Malignant Syndrome
- Medication-Related Endocrine and Metabolic Disturbances
- Teratogenicity and Reproductive Toxicity
- Baseline Risk Assessment and Organ-Specific Monitoring
- Reversibility, Persistence, and Cumulative Toxicity
17Drug Information and Therapeutic Evidence14 argomenti
- Reading Prescribing Information and Product Monographs
- Indications, Contraindications, Warnings, and Precautions
- Using Formularies and Independent Drug References
- Interpreting Clinical Practice Guidelines
- Patient-Relevant and Surrogate Outcomes
- Relative Effects, Absolute Effects, and Baseline Risk
- Numbers Needed to Treat and Harm
- Confidence Intervals and Clinical Importance
- Applicability of Trial Results to an Individual Patient
- Comparative Effectiveness and Active Comparators
- Interpreting Subgroup and Post Hoc Findings
- Recognizing Publication Bias and Promotional Claims
- Off-Label Use and the Strength of Supporting Evidence
- Reconciling Conflicting or Changing Recommendations
18Rational Prescribing and Treatment Planning14 argomenti
- Defining the Problem That Requires Treatment
- Setting Measurable Therapeutic Goals
- Considering Nonpharmacological Alternatives and Adjuncts
- Selecting a Drug Class and Individual Medicine
- Comparing Benefit, Harm, Convenience, and Cost
- Checking Comorbidities, Contraindications, and Interactions
- Choosing Dose, Route, Frequency, and Duration
- Writing Clear and Complete Medication Orders
- Planning Baseline Tests and Follow-Up
- Defining Response, Failure, and Stopping Criteria
- Starting, Titrating, Switching, and Combining Medicines
- Rescue Therapy and Maintenance Therapy
- Communicating Uncertainty and Patient Preferences
- Documenting the Rationale for Treatment
19Medication Histories, Communication, and Adherence13 argomenti
- Constructing a Complete Medication History
- Including Nonprescription Medicines and Supplements
- Verifying What the Patient Actually Takes
- Identifying Duplicate Ingredients and Therapeutic Duplication
- Intentional and Unintentional Nonadherence
- Financial, Cognitive, Physical, and Practical Barriers
- Explaining Expected Benefits and Time to Response
- Communicating Common and Serious Adverse Effects
- Teach-Back and Accessible Medication Instructions
- Simplifying Regimens and Aligning Dosing Schedules
- Missed Doses and Product-Specific Advice
- Supporting Caregivers and Shared Medication Decisions
- Reviewing Adherence Before Escalating Therapy
20Pharmacogenetics in Drug Therapy13 argomenti
- Genetic Contributions to Pharmacokinetic Variability
- Genetic Contributions to Pharmacodynamic Variability
- Genotype, Predicted Phenotype, and Observed Response
- Poor, Intermediate, Normal, Rapid, and Ultrarapid Metabolism
- CYP2D6 and CYP2C19 Drug-Response Examples
- TPMT and NUDT15 in Thiopurine Therapy
- DPYD and Fluoropyrimidine Toxicity
- HLA-Associated Drug Hypersensitivity
- Transporter Variants and Drug Exposure
- Phenoconversion Caused by Interacting Medicines
- Applying Validated Drug-Gene Guidance
- Limits of Association Tables and Commercial Reports
- Integrating Genetic Results with Clinical Monitoring
21Biologics and Advanced Therapeutic Modalities14 argomenti
- Small Molecules and Biological Medicines
- Therapeutic Proteins, Peptides, and Enzymes
- Monoclonal Antibodies and Antibody Fragments
- Target-Mediated Drug Disposition
- Fc-Mediated Effects and Antibody Half-Life
- Immunogenicity and Antidrug Antibodies
- Biosimilars and Product-Specific Substitution Rules
- Antisense Oligonucleotides and RNA Interference
- Messenger RNA as a Therapeutic Platform
- Gene Addition and Gene Editing as Treatment Modalities
- Cell-Based Medicines and Persistence of Effect
- Delivery, Tissue Access, and Durability Limitations
- Infusion Reactions and Modality-Specific Toxicities
- Long-Term Monitoring of Advanced Therapies
22Pharmacotherapy During Pregnancy and Lactation12 argomenti
- Maternal Pharmacokinetic Changes During Pregnancy
- Gestational Timing and Fetal Susceptibility
- Placental Exposure and Drug Selection
- Balancing Untreated Disease and Treatment Risks
- Evaluating Human Pregnancy Safety Evidence
- Preconception Medication Review
- Medicines with Important Teratogenic Risks
- Treatment Changes Across Pregnancy and Postpartum
- Drug Transfer into Human Milk
- Infant Exposure and Factors Affecting Risk
- Choosing Medicines During Breastfeeding
- Counseling Under Uncertainty
23Pediatric and Neonatal Pharmacology12 argomenti
- Developmental Changes in Drug Absorption
- Age-Dependent Distribution and Protein Binding
- Maturation of Metabolism and Renal Elimination
- Neonatal and Pediatric Differences in Drug Response
- Weight-Based Dosing and Dose Limits
- Developmentally Appropriate Dosage Forms
- Excipients of Concern in Infants and Children
- Measuring and Administering Oral Liquids
- Off-Label Pediatric Use and Evidence Limitations
- Preventing Tenfold and Concentration Errors
- Monitoring Growth and Development During Therapy
- Supporting Adherence Across Childhood and Adolescence
24Geriatric Pharmacology12 argomenti
- Age-Related Changes in Drug Disposition
- Increased Pharmacodynamic Sensitivity
- Frailty and Physiological Reserve
- Multimorbidity and Competing Treatment Priorities
- Anticholinergic and Sedative Medication Burden
- Medicines Associated with Falls and Orthostatic Symptoms
- Renal Function Assessment in Older Adults
- Cognitive Impairment and Medication Management
- Potentially Inappropriate Medicines and Contextual Judgment
- Time to Benefit and Remaining Treatment Horizon
- Preventive Therapy in Advanced Frailty
- Patient Goals, Function, and Quality of Life
25Prescribing in Organ Dysfunction and Altered Physiology14 argomenti
- Selecting Renal Function Estimates for Drug Dosing
- Stable Chronic Kidney Disease and Dose Adjustment
- Acute Kidney Injury and Rapidly Changing Clearance
- Dialysis Timing and Supplemental Dosing Concepts
- Hepatic Impairment and Its Assessment Limitations
- Hypoalbuminemia and Interpretation of Drug Exposure
- Heart Failure and Altered Organ Perfusion
- Obesity and Drug-Specific Body-Size Scaling
- Cachexia, Malnutrition, and Low Body Mass
- Burns, Sepsis, and Expanded Distribution Volumes
- Augmented Renal Clearance
- Extracorporeal Circuits and Drug Sequestration
- Bariatric Surgery and Altered Oral Exposure
- Reassessing Regimens as Physiology Changes
Tappa 3
Nervous System Pharmacology
Farmaci per dolore, umore, sonno e crisi epilettiche
14 moduli · 173 argomenti
26Cholinergic Pharmacology10 argomenti
- Muscarinic and Nicotinic Receptor Pharmacology
- Direct-Acting Cholinergic Agonists
- Reversible Acetylcholinesterase Inhibitors
- Irreversible Acetylcholinesterase Inhibition
- Organ-Specific Effects of Cholinergic Stimulation
- Muscarinic Antagonists and Their Selectivity
- Central and Peripheral Antimuscarinic Effects
- Therapeutic Uses of Cholinergic and Anticholinergic Drugs
- Cholinergic Excess and Anticholinergic Toxicity
- Cumulative Antimuscarinic Exposure Across Drug Classes
27Adrenergic Pharmacology12 argomenti
- Alpha and Beta Adrenoceptor Subtypes
- Catecholamine Synthesis, Storage, and Inactivation as Targets
- Direct and Indirect Sympathomimetics
- Alpha-1 and Alpha-2 Agonists
- Beta-1, Beta-2, and Beta-3 Agonists
- Mixed Adrenergic Agonists
- Selective and Nonselective Alpha Blockers
- Selective and Nonselective Beta Blockers
- Partial Agonist Activity and Additional Vasodilator Effects
- Central Sympatholytic Medicines
- Receptor Selectivity and Dose-Dependent Effects
- Withdrawal and Rebound After Adrenergic Drug Therapy
28Autacoids, Allergy, and Inflammatory Mediators12 argomenti
- Histamine Receptors and Their Pharmacological Roles
- Sedating and Less-Sedating H1 Antihistamines
- H2 Receptor Antagonists
- Leukotriene Synthesis and Receptor Inhibition
- Prostaglandins and Prostacyclin Pathways
- Bradykinin and Kallikrein-Targeted Medicines
- Mast Cell Stabilizers
- Anti-IgE and Other Targeted Allergy Treatments
- Pharmacotherapy of Allergic Rhinitis and Urticaria
- Drug Treatment of Anaphylaxis
- Pharmacological Management of Hereditary Angioedema
- Limits of Symptomatic Treatment in Allergic Emergencies
29Nonopioid Analgesics and Anti-Inflammatory Medicines12 argomenti
- Paracetamol and Acetaminophen Pharmacology
- Nonselective Cyclooxygenase Inhibitors
- Selective COX-2 Inhibitors
- Aspirin as an Analgesic and Anti-Inflammatory Drug
- Topical Nonsteroidal Anti-Inflammatory Drugs
- Gastrointestinal, Renal, and Cardiovascular NSAID Risks
- NSAID-Related Bronchospasm and Hypersensitivity
- Gastroprotection During Anti-Inflammatory Therapy
- Analgesic Selection for Acute Musculoskeletal Pain
- Analgesic Selection for Chronic Pain
- Combining Nonopioid Agents Without Ingredient Duplication
- Duration, Reassessment, and Functional Treatment Goals
30Opioids and Multimodal Pain Pharmacotherapy14 argomenti
- Opioid Receptor Subtypes and Signaling
- Full and Partial Opioid Agonists
- Opioid Antagonists and Reversal of Effects
- Immediate-Release and Extended-Release Opioids
- Analgesia, Sedation, and Respiratory Depression
- Opioid-Induced Constipation and Its Treatment
- Tolerance, Dependence, and Opioid-Induced Hyperalgesia
- Neuropathic Pain Adjuvants
- Topical Lidocaine and Capsaicin
- Combining Analgesics with Different Mechanisms
- Opioid Rotation and Incomplete Cross-Tolerance
- Risk Assessment and Monitoring During Opioid Therapy
- Tapering and Management of Withdrawal Symptoms
- Balancing Pain Relief, Function, and Treatment Burden
31Anesthesia, Sedation, and Neuromuscular Blockade14 argomenti
- Local Anesthetic Sodium Channel Blockade
- Amide and Ester Local Anesthetics
- Local Anesthetic Potency, Onset, and Duration
- Local Anesthetic Systemic Toxicity
- Inhaled General Anesthetics
- Intravenous Anesthetics and Sedative Agents
- Dissociative Anesthesia and Ketamine Pharmacology
- Benzodiazepines and Sedation Reversal
- Analgesia, Amnesia, Hypnosis, and Immobility
- Depolarizing Neuromuscular Blockers
- Nondepolarizing Neuromuscular Blockers
- Reversal of Neuromuscular Blockade
- Malignant Hyperthermia and Triggering Medicines
- Pharmacological Recovery and Residual Drug Effects
32Antiseizure Medicines12 argomenti
- Sodium Channel-Modulating Antiseizure Drugs
- Calcium Channel and Synaptic Vesicle Targets
- GABA-Enhancing Mechanisms
- Glutamatergic Targets and Other Mechanisms
- Broad-Spectrum and Seizure-Specific Treatment Choices
- Monotherapy and Rational Combination Therapy
- Enzyme-Inducing and Enzyme-Inhibiting Antiseizure Drugs
- Therapeutic Monitoring of Selected Antiseizure Medicines
- Cognitive, Behavioral, and Systemic Adverse Effects
- Antiseizure Treatment and Reproductive Considerations
- Rescue Medicines and Status Epilepticus Treatment Principles
- Treatment Withdrawal and Recurrence Risk
33Movement Disorders and Neurodegenerative Therapeutics13 argomenti
- Levodopa and Peripheral Decarboxylase Inhibitors
- Dopamine Agonists
- MAO-B and COMT Inhibitors
- Amantadine and Anticholinergic Treatments
- Wearing-Off, Dyskinesia, and Motor Fluctuations
- Neuropsychiatric Effects of Parkinsonian Medicines
- Medicines for Essential Tremor
- VMAT2 Inhibitors for Selected Movement Disorders
- Cholinesterase Inhibitors in Dementia
- Memantine and Glutamatergic Modulation
- Disease-Modifying Alzheimer Therapies and Monitoring Burden
- Pharmacological Treatment of Motor Neuron Disease
- Symptom Relief and Realistic Treatment Outcomes
34Migraine and Headache Pharmacotherapy11 argomenti
- Acute and Preventive Treatment Objectives
- Triptans and Serotonin Receptor Selectivity
- Gepants and CGRP Receptor Antagonism
- Ditans and Nonvasoconstrictive Serotonergic Therapy
- CGRP-Targeted Monoclonal Antibodies
- Established Oral Migraine Preventive Medicines
- Botulinum Toxin in Chronic Migraine
- Antiemetic Use in Migraine Treatment
- Medication-Overuse Headache
- Pharmacotherapy of Cluster Headache
- Treatment Selection with Cardiovascular and Reproductive Constraints
35Neuroimmune and Neuromuscular Pharmacotherapy11 argomenti
- Multiple Sclerosis Disease-Modifying Treatment Classes
- Immune Trafficking and Lymphocyte-Targeted Therapies
- Treatment of Acute Neuroinflammatory Relapses
- Infection Risks and Monitoring During Neuroimmune Therapy
- Symptomatic Treatment of Spasticity
- Acetylcholinesterase Inhibitors in Myasthenia Gravis
- Immunosuppressive Treatment of Neuromuscular Autoimmunity
- Complement and FcRn Inhibitors in Selected Disorders
- Immunoglobulin Therapy in Neurological Disease
- Botulinum Toxins for Focal Muscle Overactivity
- Medicines That Worsen Neuromuscular Transmission
36Antidepressants and Anxiolytic Medicines14 argomenti
- Selective Serotonin Reuptake Inhibitors
- Serotonin-Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
- Other Antidepressant Mechanisms
- Delayed Therapeutic Effects and Early Adverse Effects
- Antidepressant Selection by Symptoms and Comorbidities
- Benzodiazepines in Anxiety Treatment
- Buspirone and Other Nonbenzodiazepine Options
- Treatment Response, Remission, and Relapse Prevention
- Switching Antidepressants and Washout Requirements
- Augmentation and Treatment-Resistant Depression
- Antidepressant Discontinuation Symptoms
- Monitoring Activation, Mood Switching, and Suicide Risk
37Antipsychotics and Mood Stabilizers14 argomenti
- Dopamine Receptor Antagonism and Partial Agonism
- First-Generation and Second-Generation Antipsychotics
- Oral and Long-Acting Injectable Formulations
- Extrapyramidal Symptoms and Their Management
- Tardive Dyskinesia and Treatment Options
- Metabolic, Endocrine, and Cardiovascular Adverse Effects
- Clozapine and Required Clinical Monitoring
- Lithium Pharmacology and Concentration Monitoring
- Antiseizure Medicines Used as Mood Stabilizers
- Pharmacotherapy of Acute Mania
- Pharmacotherapy of Bipolar Depression
- Maintenance Treatment and Relapse Prevention
- Distinguishing Therapeutic Nonresponse from Inadequate Exposure
- Combined Treatment and Cumulative Adverse Effects
38Sleep, Wakefulness, and Attention Therapies11 argomenti
- Benzodiazepine Receptor Agonists for Insomnia
- Melatonin and Melatonin Receptor Agonists
- Orexin Receptor Antagonists
- Sedating Medicines and Off-Label Sleep Treatment
- Next-Day Impairment, Falls, and Complex Sleep Behaviors
- Stimulants for Attention-Deficit/Hyperactivity Disorder
- Nonstimulant ADHD Medicines
- Cardiovascular, Growth, and Psychiatric Monitoring in ADHD
- Wake-Promoting Agents for Selected Sleep Disorders
- Medicines for Narcolepsy and Cataplexy
- Dependence, Misuse, and Treatment Reassessment
39Pharmacotherapy of Substance Use Disorders13 argomenti
- Therapeutic Goals in Addiction Treatment
- Nicotine Replacement Products
- Varenicline and Bupropion for Tobacco Cessation
- Methadone and Buprenorphine in Opioid Use Disorder
- Naltrexone and Opioid Receptor Blockade
- Naloxone for Opioid Overdose Reversal
- Precipitated Withdrawal and Treatment Transitions
- Medicines for Alcohol Use Disorder
- Pharmacological Management of Alcohol Withdrawal
- Thiamine in Patients at Risk of Deficiency
- Sedative Dependence and Supervised Withdrawal Principles
- Evidence Gaps in Stimulant Use Disorder Pharmacotherapy
- Combining Medication with Psychosocial Treatment
Tappa 4
Organ-System Therapeutics
Cuore, polmoni, intestino, ormoni, immunità
19 moduli · 249 argomenti
40Antihypertensive Pharmacotherapy13 argomenti
- Renin-Angiotensin-Aldosterone System Targets
- ACE Inhibitors and Angiotensin Receptor Blockers
- Dihydropyridine Calcium Channel Blockers
- Nondihydropyridine Calcium Channel Blockers
- Thiazide and Thiazide-Like Diuretics in Hypertension
- Beta Blockers in Selected Hypertensive Patients
- Mineralocorticoid Receptor Antagonists
- Alpha Blockers, Central Agents, and Direct Vasodilators
- Initial Therapy and Combination Treatment Principles
- Hypertension with Kidney Disease, Diabetes, or Pregnancy
- Resistant Hypertension and Medication Review
- Orthostatic Hypotension and Treatment Tolerability
- Laboratory and Clinical Monitoring of Antihypertensive Therapy
41Ischemic Heart Disease Pharmacotherapy11 argomenti
- Symptom Control and Cardiovascular Event Prevention
- Organic Nitrates and Nitric Oxide Signaling
- Nitrate Tolerance and Important Drug Interactions
- Beta Blockers in Angina
- Calcium Channel Blockers in Angina
- Other Antianginal Mechanisms and Selected Uses
- Pharmacological Management of Vasospastic Angina
- Antithrombotic Treatment in Acute Coronary Syndromes
- Secondary Prevention After Myocardial Infarction
- Persistent Angina and Treatment Reassessment
- Balancing Ischemic Benefit and Bleeding Risk
42Heart Failure Pharmacotherapy14 argomenti
- Treatment Objectives Across Heart Failure Phenotypes
- ACE Inhibitors, ARBs, and Angiotensin Receptor-Neprilysin Inhibition
- Evidence-Based Beta Blockade in Heart Failure
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
- SGLT2 Inhibitors in Heart Failure
- Diuretics for Congestion Relief
- Hydralazine and Nitrate Combinations
- Ivabradine and Selected Heart Rate Reduction
- Digoxin: Selected Roles and Toxicity
- Intravenous Inotropes and Their Limitations
- Initiation, Titration, and Combination Tolerability
- Monitoring Blood Pressure, Renal Function, and Potassium
- Medicines That Can Worsen Heart Failure
- Transitioning from Acute Stabilization to Long-Term Therapy
43Antiarrhythmic Pharmacology13 argomenti
- Cardiac Ion Channels as Drug Targets
- Sodium Channel-Blocking Antiarrhythmics
- Beta Blockers for Arrhythmia Management
- Potassium Channel-Blocking Antiarrhythmics
- Rate-Limiting Calcium Channel Blockers
- Adenosine and Acute Supraventricular Tachycardia
- Amiodarone and Multiorgan Toxicity
- Rate Control and Rhythm Control Objectives
- Drug Selection in Structural Heart Disease
- QT Prolongation and Torsades de Pointes Risk
- Proarrhythmia and Electrolyte Interactions
- Antiarrhythmic Loading, Accumulation, and Monitoring
- Bradycardia, Conduction Block, and Treatment Interactions
44Lipid-Lowering and Atherosclerotic Risk Reduction11 argomenti
- Statins and HMG-CoA Reductase Inhibition
- Ezetimibe and Intestinal Cholesterol Absorption
- PCSK9-Targeted Antibodies and RNA-Based Therapy
- Bempedoic Acid and ATP Citrate Lyase Inhibition
- Bile Acid Sequestrants
- Fibrates and Triglyceride-Lowering Therapy
- Prescription Omega-3 Products and Product-Specific Evidence
- Selecting Treatment by Cardiovascular Risk and Lipid Pattern
- Muscle Symptoms, Liver Tests, and Drug Interactions
- Statin Intolerance and Alternative Treatment Strategies
- Combination Therapy and Follow-Up Lipid Assessment
45Antiplatelet, Anticoagulant, and Fibrinolytic Medicines16 argomenti
- Aspirin and Irreversible Platelet Cyclooxygenase Inhibition
- P2Y12 Receptor Inhibitors
- Other Platelet-Targeted Medicines
- Unfractionated and Low-Molecular-Weight Heparins
- Fondaparinux and Indirect Factor Xa Inhibition
- Vitamin K Antagonists
- Direct Oral Anticoagulants
- Parenteral Direct Thrombin Inhibitors
- Fibrinolytic Drugs and Their Therapeutic Contexts
- Antifibrinolytic Medicines
- Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
- Laboratory Monitoring and Assay Limitations
- Bleeding Management and Anticoagulant Reversal
- Heparin-Induced Thrombocytopenia
- Periprocedural Interruption and Bridging Decisions
- Duration, Combination Therapy, and Reassessment of Bleeding Risk
46Diuretics and Renal Pharmacotherapy13 argomenti
- Nephron Sites of Diuretic Action
- Loop Diuretics
- Thiazide and Thiazide-Like Diuretics
- Potassium-Sparing Diuretics
- Carbonic Anhydrase Inhibitors
- Osmotic Diuretics
- Vasopressin Receptor Antagonists
- Diuretic Resistance and Sequential Nephron Blockade
- Monitoring Volume Status and Electrolyte Loss
- Pharmacological Kidney Protection in Chronic Disease
- Medicines for Complications of Chronic Kidney Disease
- Drug-Induced Changes in Creatinine Without Reduced Filtration
- Avoiding Nephrotoxic Combinations
47Fluids, Electrolytes, and Acid-Base Therapies13 argomenti
- Crystalloid Solutions and Their Composition
- Colloid Solutions and Clinical Limitations
- Maintenance, Replacement, and Resuscitation Objectives
- Sodium Disorders and Controlled Correction Principles
- Potassium Replacement and Administration Risks
- Pharmacological Management of Hyperkalemia
- Magnesium and Calcium Replacement
- Phosphate Replacement
- Bicarbonate and Other Alkalinizing Therapies
- Oral Rehydration Formulations
- Glucose-Containing Fluids and Metabolic Effects
- Fluid Overload and Treatment Reassessment
- Monitoring During Intravenous Fluid and Electrolyte Therapy
48Respiratory Pharmacotherapy14 argomenti
- Short-Acting and Long-Acting Beta-2 Agonists
- Short-Acting and Long-Acting Muscarinic Antagonists
- Inhaled Corticosteroids
- Combination Inhalers and Regimen Selection
- Leukotriene Modifiers in Airway Disease
- Biologic Therapies for Severe Asthma
- Systemic Corticosteroids in Respiratory Exacerbations
- Phosphodiesterase Inhibitors and Other Selected COPD Therapies
- Reliever and Controller Treatment Strategies
- Inhaler Technique, Adherence, and Local Adverse Effects
- Antifibrotic Medicines for Selected Interstitial Lung Diseases
- Pulmonary Arterial Hypertension Drug Classes
- CFTR Modulators and Disease-Specific Respiratory Therapy
- Cough Medicines, Mucolytics, and Evidence Limitations
49Acid-Related Disorders, Nausea, and Gastric Motility13 argomenti
- Proton Pump Inhibitors
- Histamine H2 Receptor Blockade
- Antacids, Alginates, and Mucosal Protectants
- Gastroesophageal Reflux Pharmacotherapy
- Peptic Ulcer Treatment and Helicobacter pylori Eradication Principles
- Stress Ulcer Prophylaxis and Appropriate Selection
- Serotonin 5-HT3 Receptor Antagonists
- Dopamine Antagonists and Prokinetic Medicines
- Neurokinin-1 Receptor Antagonists
- Antihistamine and Antimuscarinic Antiemetics
- Antiemetic Combinations by Clinical Setting
- Gastroparesis Treatment and Limitations
- Long-Term Acid Suppression and Deprescribing
50Intestinal, Pancreatic, and Hepatic Pharmacotherapy13 argomenti
- Bulk-Forming, Osmotic, and Stimulant Laxatives
- Intestinal Secretagogues and Motility-Targeted Medicines
- Antidiarrheal Medicines and Their Contraindications
- Pharmacological Treatment of Irritable Bowel Syndrome
- Aminosalicylates in Inflammatory Bowel Disease
- Corticosteroid Induction and Steroid-Sparing Maintenance
- Biologic and Targeted Small-Molecule IBD Therapies
- Pancreatic Enzyme Replacement
- Bile Acid-Targeted Medicines
- Pharmacological Treatment of Hepatic Encephalopathy
- Medicines for Portal Hypertension and Variceal Bleeding
- Ascites Pharmacotherapy and Monitoring
- Therapeutic Limitations in Advanced Liver Disease
51Diabetes Pharmacotherapy15 argomenti
- Insulin Preparations and Time-Action Profiles
- Basal, Prandial, and Correction Insulin Concepts
- Insulin Administration and Concentration Safety
- Metformin and Hepatic Glucose Production
- Sulfonylureas and Meglitinides
- Thiazolidinediones
- DPP-4 Inhibitors
- GLP-1 Receptor Agonists and Dual Incretin Agonists
- SGLT2 Inhibitors
- Alpha-Glucosidase Inhibitors and Other Selected Agents
- Selecting Therapy for Glycemic and Cardiorenal Goals
- Hypoglycemia Risk and Rescue Medicines
- Sick-Day Medication Management Principles
- Treatment Intensification and Deintensification
- Monitoring Efficacy, Weight, Renal Function, and Adverse Effects
52Obesity and Weight-Management Pharmacotherapy11 argomenti
- Indications and Goals of Weight-Management Medicines
- Appetite, Satiety, and Energy Intake as Drug Targets
- Incretin-Based Weight-Management Therapies
- Centrally Acting Anti-Obesity Medicines
- Gastrointestinal Lipase Inhibition
- Treatment Selection with Psychiatric and Cardiovascular Comorbidities
- Tolerability, Nutritional Intake, and Lean-Mass Considerations
- Assessing Response and Criteria for Continuing Treatment
- Weight Recurrence After Discontinuation
- Interactions with Other Long-Term Medicines
- Product Quality and Risks of Unverified Preparations
53Thyroid, Adrenal, and Pituitary Pharmacology15 argomenti
- Thyroid Hormone Replacement
- Thionamides and Thyroid Hormone Synthesis Inhibition
- Iodide and Radioiodine in Selected Thyroid Treatments
- Monitoring and Interactions in Thyroid Therapy
- Glucocorticoid Receptor Pharmacology
- Mineralocorticoid Replacement
- Systemic Corticosteroid Potency and Duration
- Hypothalamic-Pituitary-Adrenal Suppression
- Corticosteroid Tapering and Stress Coverage Principles
- Steroidogenesis Inhibitors and Cortisol Receptor Antagonism
- Growth Hormone and Growth Hormone Antagonists
- Somatostatin Analogs
- Dopamine Agonists for Hyperprolactinemia
- Vasopressin Analogs and Desmopressin
- Endocrine Replacement Monitoring and Overtreatment
54Reproductive and Sexual Health Pharmacotherapy14 argomenti
- Estrogens, Progestogens, and Their Receptor Effects
- Combined and Progestogen-Only Contraceptives
- Long-Acting Contraceptive Drug Formulations
- Emergency Contraceptive Medicines
- Drug Interactions That Affect Contraceptive Efficacy
- Menopausal Hormone Therapy and Individual Risk Assessment
- Androgen Replacement and Antiandrogens
- GnRH Agonists and Antagonists
- Pharmacological Ovulation Induction
- Medicines for Endometriosis and Heavy Menstrual Bleeding
- Uterotonic and Tocolytic Medicines
- Pharmacology of Medication Abortion
- Medicines for Erectile Dysfunction
- Reproductive Counseling for Teratogenic Medicines
55Urological Pharmacotherapy10 argomenti
- Alpha-1 Blockers for Lower Urinary Tract Symptoms
- 5-Alpha-Reductase Inhibitors
- Combination Treatment for Benign Prostatic Enlargement
- Antimuscarinic Medicines for Overactive Bladder
- Beta-3 Agonists for Overactive Bladder
- Intravesical Botulinum Toxin Pharmacology
- Selected Drug Treatment of Nocturia
- Medicines Used in Urinary Stone Prevention
- Urinary Retention and Medication-Related Symptoms
- Monitoring Blood Pressure, Cognition, and Urinary Effects
56Bone and Mineral Metabolism Therapies13 argomenti
- Calcium and Vitamin D Preparations
- Active Vitamin D Analogs
- Bisphosphonates
- RANKL Inhibition
- Parathyroid Hormone Receptor Agonists
- Sclerostin Inhibition
- Selective Estrogen Receptor Modulators
- Calcimimetics
- Phosphate Binders
- Antiresorptive and Anabolic Treatment Sequencing
- Hypocalcemia, Jaw Osteonecrosis, and Atypical Fracture Risks
- Treatment Interruption and Rebound Bone Loss
- Monitoring Skeletal Treatment Response
57Rheumatology and Immune-Mediated Inflammatory Disease14 argomenti
- Conventional Synthetic Disease-Modifying Antirheumatic Drugs
- Methotrexate Pharmacology and Weekly-Dosing Safety
- Antimalarial Medicines in Autoimmune Disease
- TNF Inhibitors
- Interleukin-Targeted Therapies
- B-Cell-Directed and T-Cell Costimulation Therapies
- Janus Kinase Inhibitors
- Treat-to-Target and Steroid-Sparing Strategies
- Screening and Monitoring Before Immunomodulatory Therapy
- Infection, Malignancy, and Thrombotic Risk Assessment
- Medicines for Acute Gout Flares
- Xanthine Oxidase Inhibitors and Uricosurics
- Urate-Lowering Initiation, Prophylaxis, and Monitoring
- Switching Mechanisms After Inadequate Response
58Transplantation and Systemic Immunosuppression13 argomenti
- Calcineurin Inhibitors
- Antimetabolite Immunosuppressants
- mTOR Inhibitors
- Corticosteroids in Transplant Regimens
- Lymphocyte-Depleting and Nondepleting Antibodies
- Costimulation Blockade
- Induction, Maintenance, and Rejection Treatment Objectives
- Immunosuppressant Concentration Monitoring
- Interactions with Anti-Infective Medicines
- Infection Prophylaxis During Immunosuppression
- Nephrotoxicity, Metabolic Effects, and Malignancy Risk
- Adherence and Consequences of Interrupted Treatment
- Balancing Graft Protection and Treatment Toxicity
Tappa 5
Anti-Infectives & Oncology
La lotta a infezioni e cancro
14 moduli · 184 argomenti
59Principles of Anti-Infective Pharmacology14 argomenti
- Selective Toxicity and Antimicrobial Targets
- Spectrum of Activity and Clinical Coverage
- Bactericidal and Bacteriostatic Activity in Context
- Minimum Inhibitory Concentrations and Susceptibility Categories
- Time-Dependent and Concentration-Dependent Activity
- AUC-to-MIC and Other Exposure Targets
- Post-Antibiotic Effects
- Tissue Penetration and Infection-Site Exposure
- Inoculum, Biofilms, and Limits of Drug Activity
- Intrinsic and Acquired Resistance Relevant to Treatment
- Combination Therapy, Synergy, and Antagonism
- Host Factors That Change Anti-Infective Selection
- Prophylactic, Empiric, and Targeted Treatment
- Source Control as a Requirement for Effective Therapy
60Beta-Lactams and Other Cell Wall-Active Antibiotics13 argomenti
- Penicillins and Their Antibacterial Spectra
- Cephalosporin Families and Spectrum Differences
- Carbapenems
- Monobactams
- Beta-Lactamase Inhibitors
- Beta-Lactam and Beta-Lactamase Inhibitor Combinations
- Penicillin-Binding Proteins and Resistance
- Glycopeptides and Lipoglycopeptides
- Fosfomycin and Other Cell Wall-Active Agents
- Beta-Lactam Allergy and Cross-Reactivity Assessment
- Infusion Strategies and Pharmacodynamic Exposure
- Renal Adjustment and Neurotoxicity Risks
- Monitoring Glycopeptide Exposure and Toxicity
61Other Antibacterial Drug Classes14 argomenti
- Aminoglycosides
- Macrolides and Ketolides
- Tetracyclines and Related Agents
- Lincosamides
- Oxazolidinones
- Fluoroquinolones
- Folate Antagonists and Combination Therapy
- Nitroimidazoles
- Nitrofurantoin and Urinary Antibacterial Activity
- Lipopeptides and Membrane-Active Antibiotics
- Polymyxins and Toxicity Limitations
- Rifamycins and Major Drug Interactions
- Class-Specific Resistance and Cross-Resistance
- Comparing Major Toxicities Across Antibacterial Classes
62Antibacterial Therapeutics and Stewardship16 argomenti
- Choosing Empiric Therapy for the Clinical Syndrome
- Incorporating Local Susceptibility Information
- Antibiotic Selection for Respiratory Infections
- Antibiotic Selection for Urinary Tract Infections
- Antibiotic Selection for Skin and Soft Tissue Infections
- Antibiotic Selection for Intra-Abdominal Infections
- Treatment Principles for Bloodstream and Endovascular Infections
- Central Nervous System Infection and Drug Penetration
- Antibacterial Treatment in Immunocompromised Patients
- Surgical and Procedure-Related Antibiotic Prophylaxis
- Culture-Guided De-Escalation
- Intravenous-to-Oral Switching
- Choosing and Reassessing Treatment Duration
- Clostridioides difficile-Associated Disease and Drug Selection
- WHO AWaRe Categories and Responsible Antibiotic Use
- Distinguishing Colonization from a Treatment Indication
63Antimycobacterial Pharmacotherapy11 argomenti
- Isoniazid, Rifamycins, Pyrazinamide, and Ethambutol
- Why Active Tuberculosis Requires Combination Treatment
- Drug-Susceptible and Drug-Resistant Treatment Principles
- Fluoroquinolones in Selected Mycobacterial Regimens
- Bedaquiline, Pretomanid, and Other Specialized Agents
- Mycobacterial Treatment Toxicities and Monitoring
- Rifamycin Interactions and Regimen Compatibility
- Preventive Treatment for Latent Tuberculosis Infection
- Treatment Adherence and Consequences of Interruption
- Nontuberculous Mycobacterial Drug Treatment
- Antileprosy Medicines
64Antifungal Pharmacology and Therapeutics13 argomenti
- Polyene Antifungals
- Azole Antifungals
- Echinocandins
- Flucytosine
- Allylamines and Other Superficial Antifungals
- Superficial, Mucosal, and Invasive Treatment Objectives
- Candida Infection and Drug Selection
- Aspergillus and Other Invasive Mold Infections
- Cryptococcal Treatment Principles
- Antifungal Prophylaxis in Selected High-Risk Patients
- Antifungal Drug Interactions and Liver Toxicity
- Therapeutic Monitoring of Selected Antifungals
- Resistance, Tissue Penetration, and Treatment Failure
65Antiviral Pharmacology and Therapeutics15 argomenti
- Viral Entry, Replication, and Maturation as Drug Targets
- Antiherpesvirus Nucleoside Analogs
- Cytomegalovirus-Directed Medicines
- Influenza Antivirals
- Coronavirus-Directed Antivirals and Interaction Assessment
- HIV Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
- HIV Integrase and Protease Inhibitors
- HIV Entry, Fusion, and Capsid Inhibitors
- Combination Antiretroviral Therapy and Resistance Prevention
- Long-Acting Antiretroviral Formulations
- Hepatitis B Antiviral Therapy
- Direct-Acting Hepatitis C Antivirals
- Preexposure and Postexposure Antiviral Prophylaxis
- Renal, Bone, Metabolic, and Hepatic Monitoring
- Adherence, Drug Interactions, and Virological Failure
66Antiparasitic Pharmacotherapy12 argomenti
- Antimalarial Drug Classes and Parasite-Stage Activity
- Combination Antimalarial Treatment Principles
- Malaria Chemoprophylaxis and Resistance Considerations
- Radical Cure, Hypnozoites, and G6PD-Related Drug Risk
- Medicines for Amoebiasis and Giardiasis
- Pharmacotherapy of Toxoplasmosis
- Medicines for Leishmaniasis and Trypanosomiasis
- Benzimidazole Anthelmintics
- Ivermectin and Related Antiparasitic Uses
- Praziquantel and Other Selected Anthelmintics
- Ectoparasiticides
- Pregnancy, Organ Function, and Parasite-Specific Treatment Constraints
67Vaccines and Passive Immunoprophylaxis12 argomenti
- Live Attenuated and Inactivated Vaccines
- Protein, Polysaccharide, and Conjugate Vaccines
- Viral Vector and Nucleic Acid Vaccine Platforms
- Adjuvants and Immune Response Enhancement
- Primary Series, Boosters, and Waning Protection
- Passive Immunization with Immunoglobulins
- Monoclonal Antibodies for Infection Prevention
- Preexposure and Postexposure Immunoprophylaxis
- Contraindications and Precautions for Vaccine Products
- Vaccination During Immunosuppressive Treatment
- Reactogenicity and Suspected Vaccine Adverse Reactions
- Storage, Handling, and Product-Specific Administration Requirements
68Cytotoxic Anticancer Pharmacology13 argomenti
- Cell Cycle Dependence and Cytotoxic Drug Action
- Alkylating Agents
- Platinum Compounds
- Antimetabolites and Folate Pathway Inhibitors
- Purine and Pyrimidine Analogs
- Anthracyclines and Other Antitumor Antibiotics
- Topoisomerase Inhibitors
- Microtubule-Targeted Medicines
- Combination Regimens and Nonoverlapping Toxicities
- Treatment Cycles, Dose Intensity, and Recovery
- Myelosuppression and Cumulative Organ Toxicity
- Resistance to Cytotoxic Treatment
- Dose Modification for Organ Dysfunction and Toxicity
69Targeted and Endocrine Anticancer Therapy14 argomenti
- Kinase Inhibitors and Oncogenic Signaling
- Growth Factor Receptor-Targeted Antibodies
- Angiogenesis Inhibitors
- PARP Inhibitors and DNA Repair Vulnerabilities
- CDK Inhibitors and Cell Cycle Targets
- Proteasome Inhibitors and Selected Epigenetic Therapies
- Antibody-Drug Conjugates
- Estrogen Receptor Modulators and Degraders
- Aromatase Inhibitors
- Androgen Deprivation and Androgen Receptor Pathway Inhibitors
- Biomarker Eligibility for Drug Selection
- Acquired Resistance and Treatment Sequencing
- Oral Anticancer Drug Interactions and Adherence
- Target-Specific Toxicity Monitoring
70Cancer Immunotherapy and Cellular Therapies12 argomenti
- Immune Checkpoint Inhibitors
- T-Cell-Engaging Bispecific Antibodies
- CAR T-Cell and Other Adoptive Cellular Therapies
- Cytokine-Based Anticancer Medicines
- Therapeutic Cancer Vaccines and Oncolytic Approaches
- Immune Activation and Delayed Treatment Effects
- Immune-Related Adverse Events
- Cytokine Release Syndrome
- Immune Effector Cell-Associated Neurotoxicity
- Pharmacological Management of Treatment-Related Immune Toxicity
- Infection Prophylaxis and Prolonged Cytopenias
- Persistence, Retreatment, and Long-Term Follow-Up
71Supportive Pharmacotherapy in Cancer Care12 argomenti
- Antiemetic Regimens by Emetogenic Risk
- Hematopoietic Growth Factors
- Prevention and Treatment of Tumor Lysis Syndrome
- Uroprotection and Other Cytoprotective Medicines
- Anticancer Drug Extravasation and Antidote Selection
- Management of Treatment-Related Diarrhea and Mucositis
- Cancer-Associated Thrombosis
- Medicines for Bone Metastases and Hypercalcemia
- Cancer Pain and Breakthrough Symptoms
- Infection Prophylaxis During Myelosuppressive Treatment
- Reproductive Risks and Fertility-Related Medication Counseling
- Supportive Care Interactions with Anticancer Regimens
72Hematological Pharmacotherapy13 argomenti
- Oral and Intravenous Iron Preparations
- Vitamin B12 and Folate Replacement
- Erythropoiesis-Stimulating Agents
- Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
- Thrombopoietin Receptor Agonists
- Hemostatic Factor Replacement Products
- Nonfactor Therapies for Hemophilia
- Medicines for Immune Thrombocytopenia
- Complement Inhibitors in Selected Hematological Disorders
- Disease-Modifying Medicines for Sickle Cell Disease
- Iron Chelation in Chronic Iron Overload
- Balancing Hematological Response and Thrombotic Risk
- Monitoring Blood Counts, Iron Status, and Treatment Toxicity
Tappa 6
Specialist Care & Medication Safety
Terapia intensiva, intossicazioni, prescrizioni più sicure
8 moduli · 107 argomenti
73Dermatological Pharmacotherapy13 argomenti
- Skin Penetration and Topical Vehicle Selection
- Topical Corticosteroid Potency and Site of Use
- Topical Calcineurin and PDE4 Inhibitors
- Topical and Systemic Retinoids
- Acne Treatment Combinations and Antibiotic Stewardship
- Pharmacotherapy of Atopic Dermatitis
- Topical and Systemic Psoriasis Treatments
- Rosacea Pharmacotherapy
- Antifungal and Antiparasitic Skin Treatments
- Keratolytics, Emollients, and Barrier Therapies
- Medicines for Alopecia and Selected Pigment Disorders
- Photosensitivity and Drug-Related Skin Injury
- Monitoring Systemic Absorption from Topical Products
74Ophthalmic and Otic Pharmacotherapy13 argomenti
- Ocular Drug Delivery and Systemic Absorption
- Prostaglandin Analogs for Glaucoma
- Ocular Beta Blockers and Alpha Agonists
- Ocular Carbonic Anhydrase and Rho Kinase Inhibitors
- Mydriatic and Cycloplegic Medicines
- Ocular Anti-Inflammatory and Antiallergic Medicines
- Ophthalmic Antimicrobial Treatment
- Intravitreal Anti-VEGF Medicines
- Lubricants and Medicines for Dry Eye Disease
- Ocular Toxicity from Systemic Medicines
- Otic Anti-Infective and Anti-Inflammatory Products
- Tympanic Membrane Integrity and Otic Drug Selection
- Safe Use of Ophthalmic and Otic Formulations
75Emergency, Critical Care, and Perioperative Pharmacotherapy15 argomenti
- Vasopressors and Inotropes in Shock
- Choosing Hemodynamic Drug Targets
- Analgesia and Sedation in Critical Illness
- Medicines Used During Resuscitation
- Pharmacological Treatment of Hypertensive Emergencies
- Time-Critical Antithrombotic and Thrombolytic Treatment
- Drug Management of Severe Hypoglycemia and Hyperglycemic Crises
- Acute Adrenal and Thyroid Emergencies
- Emergency Reversal of Medication Effects
- Perioperative Continuation and Withholding of Chronic Medicines
- Thromboprophylaxis in Hospitalized Patients
- Pharmacological Components of Parenteral Nutrition
- Prevention and Management of Refeeding-Related Electrolyte Problems
- Infusion Titration, Compatibility, and Monitoring
- Reassessment as Organ Function and Clinical Status Change
76Clinical Toxicology and Antidotes15 argomenti
- Exposure History and Toxicological Risk Assessment
- Toxidromes and Their Pharmacological Basis
- Dose, Time, Formulation, and Delayed Toxicity
- Supportive Care as a Foundation of Poisoning Management
- Activated Charcoal and Its Limitations
- Enhanced Elimination and Extracorporeal Treatment Principles
- Acetaminophen Poisoning and N-Acetylcysteine
- Opioid Toxicity and Antagonist Treatment
- Salicylate and Lithium Toxicity
- Digoxin Toxicity and Antibody Fragments
- Toxic Alcohols and Alcohol Dehydrogenase Inhibition
- Cholinesterase Inhibitor Poisoning and Antidotal Therapy
- Selected Metal Poisonings and Chelation
- Antidote Adverse Effects and Monitoring
- Poison Information Services and Specialist Consultation
77Palliative and End-of-Life Pharmacotherapy13 argomenti
- Aligning Medicines with Comfort and Patient Goals
- Pain Treatment in Advanced Illness
- Pharmacological Relief of Breathlessness
- Treatment of Nausea and Vomiting in Palliative Care
- Constipation and Opioid-Related Bowel Dysfunction
- Medicines for Excess Respiratory Secretions
- Pharmacological Management of Agitation and Delirium
- Anxiety and Sleep Symptoms in Advanced Illness
- Alternative Routes When Swallowing Is Impaired
- Organ Failure and Drug Accumulation Near the End of Life
- Anticipatory Prescribing and Rescue Medicines
- Proportional Symptom Relief and Palliative Sedation Principles
- Reviewing Preventive Medicines with Limited Near-Term Benefit
78Nonprescription Medicines and Complementary Products12 argomenti
- Appropriate Scope of Nonprescription Treatment
- Reading Active Ingredients and Product Labels
- Combination Cold, Cough, and Allergy Products
- Nonprescription Analgesics and Duplicate Exposure
- Antacids, Laxatives, and Short-Term Symptom Treatments
- Vitamins and Minerals: Replacement and Excess
- Herbal Products with Pharmacological Activity
- Herb-Drug and Supplement-Drug Interactions
- Variable Composition, Contamination, and Adulteration
- Evaluating Therapeutic Claims and Evidence Quality
- Self-Treatment in Pregnancy, Childhood, and Older Age
- Persistent Symptoms and Limits of Self-Care
79Medication Safety and Pharmacovigilance12 argomenti
- Medication Errors, Adverse Reactions, and Preventable Harm
- High-Alert Medicines and Error-Prone Situations
- Look-Alike and Sound-Alike Medicine Names
- Prescribing, Dispensing, and Administration Errors
- Concentration, Route, and Formulation Mix-Ups
- Independent Checks and Safe Medication Communication
- Reporting Suspected Adverse Drug Reactions
- Postmarketing Safety Signals and Their Limitations
- Interpreting Safety Alerts and Label Changes
- Medication Incidents and Contributing System Factors
- Patient Involvement in Detecting Medication Problems
- Applying Safety Findings to Individual Treatment Plans
80Medication Review, Deprescribing, and Transitions of Care14 argomenti
- Matching Every Medicine to a Current Indication
- Identifying Prescribing Cascades
- Therapeutic Duplication and Conflicting Treatment Goals
- Assessing Cumulative Sedative, Anticholinergic, and Bleeding Risks
- Prioritizing Medicines for Review
- Time-Limited Treatment Trials
- Distinguishing Withdrawal from Disease Recurrence
- Selecting a Tapering or Direct Discontinuation Strategy
- Monitoring After Dose Reduction or Withdrawal
- Reconciliation at Admission, Transfer, and Discharge
- Communicating Reasons for Medication Changes
- Preventing Unintended Continuation of Temporary Medicines
- Follow-Up Responsibility and Continuity of Supply
- Negotiating Treatment Changes with Patients and Caregivers
Tappa 7
Practicum & Capstone
Casi reali, molti farmaci insieme
3 moduli · 38 argomenti
81Clinical Pharmacology Calculation and Monitoring Practicum11 argomenti
- Interpreting an Unfamiliar Drug Concentration-Time Profile
- Comparing Exposure Across Formulations
- Calculating a Loading and Maintenance Regimen
- Adjusting a Regimen After a Change in Renal Function
- Investigating an Unexpectedly High Trough Concentration
- Interpreting Drug Levels in Hypoalbuminemia
- Assessing a Time-Dependent Enzyme Interaction
- Detecting Errors in Weight-Based and Infusion Calculations
- Choosing a Drug Monitoring Schedule
- Distinguishing Poor Adherence from Pharmacological Failure
- Explaining Model Assumptions and Remaining Uncertainty
82Integrated Pharmacotherapy Case Studies15 argomenti
- Hypertension with Diabetes and Chronic Kidney Disease
- Heart Failure with Hypotension and Hyperkalemia
- Atrial Fibrillation with Competing Bleeding Risks
- Chronic Pain with Polypharmacy and Organ Dysfunction
- Depression with Insomnia and Medication Intolerance
- Epilepsy with Pregnancy Planning and Drug Interactions
- Asthma with Poor Inhaler Technique and Apparent Treatment Failure
- Bacterial Infection with Allergy History and Renal Impairment
- Immunosuppression with New Infection and Interacting Medicines
- Cancer Treatment with Multiple Supportive Medicines
- Pediatric Liquid Medicine and Dosing Error Prevention
- Frailty, Falls, and a Prescribing Cascade
- Suspected Drug-Induced Liver Injury
- Medication Reconciliation After a Complex Hospital Admission
- Deprescribing When Treatment Goals Change
83Integrated Pharmacology and Therapeutics Capstone12 argomenti
- Defining a Patient-Centered Therapeutic Problem
- Building an Accurate Medication and Exposure History
- Selecting Relevant Mechanistic and Clinical Evidence
- Comparing Reasonable Treatment Options
- Designing an Individualized Medication Regimen
- Checking Interactions, Contraindications, and Practical Feasibility
- Establishing Efficacy and Safety Monitoring
- Preparing a Clear Medication Explanation for the Patient
- Planning for Nonresponse, Toxicity, and Changing Circumstances
- Defining Review, Switching, and Discontinuation Criteria
- Documenting and Defending the Therapeutic Rationale
- Revising the Plan After New Clinical Information
Quindici minuti.Ogni giorno.
- 1
Una lezione entra nella pausa pranzo
Un'idea alla volta, in slide brevi. Una lezione intera dura circa quindici minuti.
- 2
Esercizi con correzione immediata
Le domande sono dentro la lezione. Rispondi e vedi subito se hai capito.
- 3
Una serie che ti fa tornare
Una lezione al giorno tiene viva la serie. Sessioni brevi e costanti ti portano fino in fondo.
- 1
Una lezione entra nella pausa pranzo
Un'idea alla volta, in slide brevi. Una lezione intera dura circa quindici minuti.
- 2
Esercizi con correzione immediata
Le domande sono dentro la lezione. Rispondi e vedi subito se hai capito.
- 3
Una serie che ti fa tornare
Una lezione al giorno tiene viva la serie. Sessioni brevi e costanti ti portano fino in fondo.
Per chi controlla la dose.
Studenti di farmacia prima degli esami di stato
Dove crescerai di più
Calcola le dosi dai dati farmacocinetici
Tappa 1 · Drug Action & PharmacokineticsInfermieri che iniziano a prescrivere
Dove crescerai di più
Individua le interazioni prima che arrivino ai pazienti
Tappa 2 · Safety, Evidence & PopulationsStudenti di medicina che vogliono che resti impresso
Dove crescerai di più
Costruisci terapie per malattie cardiache e metaboliche
Tappa 4 · Organ-System Therapeutics
Dove porta questo corso.
Il lavoro attorno a cui è costruito questo corso, e come ci si entra.
Clinical Research Associate
Monitora le sperimentazioni cliniche perché i dati siano affidabili e i pazienti protetti.
Tutte le carriere del futuroSul lavoro
- Visitare i centri della sperimentazione e confrontare i dati con i documenti originali
- Assicurarsi che una sperimentazione segua il protocollo e le regole
- Tracciare gli eventi di sicurezza e segnalarli in tempo
Come ci si entra
Di solito una laurea in scienze della vita, farmacia o infermieristica; molti iniziano come assistenti alla sperimentazione o coordinatori di centro.
Sii il primo della lista.
Accesso anticipato per i singoli, pilota per i team. Dicci chi sta imparando.
enterprise@astratrainer.com